Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx sales

This article was originally published in The Tan Sheet

Executive Summary

Effective television advertising drove a 51% increase in spoon-delivered multi-symptom cold and flu relief SKU products sales during the 2007 first quarter, the Phoenix-based Zicam manufacturer reports in a May 30 regulatory filing. The firm reports its Zicam Nasal Moisturizer product was dropped from the allergy and sinus line after it failed to gain widespread distribution in 2006, however the company plans to ramp up offerings in that category with Zicam Sinus Rapid Melt with vapor action set to launch in the second half of 2007. Quarterly net sales hit $19 mil., a 7.7% increase from a year ago, the firm says. Other results include: cold remedy product sales were up 0.4% to $11.5 mil., allergy, sinus and nasal comfort sales climbed 16.1% to $4.6 mil., cough product sales increased 8% to $1.1 mil. and multi-symptom cold and flu relief sales rose 50.9% to $1.8 mil...

You may also be interested in...



Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval

Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.

Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine

While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel